A
NEUTRAL
$135.05
Live
Agilent Technologies, Inc. · NYSE
Target $169.67
(+25.6%)
$96.43
52W Range
$160.27
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$38.29B
P/E
30.28
ROE
20.6%
Profit margin
18.8%
Debt/Equity
0.53
Dividend yield
0.74%
AI Analysis
AI-powered fundamental assessment
Confidence
78%
Agilent Technologies exhibits strong fundamental health with a Piotroski F-Score of 8/9, indicating robust accounting strength, and solid profitability metrics including an ROE of 20.62% and operating margin of 26.38%. The company is growing revenue and earnings at double-digit rates, supported by consistent earnings beat rates and strong cash flow generation, though key financial data like Altman Z-Score and cash/debt figures are missing. However, the stock trades at a premium valuation (P/E of 30.28 vs sector average of 215 but with much lower growth than peers), and insider selling activity raises caution. While analysts are bullish with a $169.67 target price, the technical trend is bearish and recent price performance has been weak over the past year despite a short-term rebound.
Key Strengths
Exceptional Piotroski F-Score of 8/9 indicates high-quality financial statements and strong operational efficiency
High profitability with ROE above 20%, operating margin near 26.4%, and gross margin over 52%
Solid earnings growth momentum: YoY EPS growth of 24.5% and Q/Q growth of 23.6%
Consistent earnings beat record: 24 out of 25 quarters beating estimates, with frequent double-digit surprises
Low debt burden with Debt/Equity ratio of 0.53 and healthy liquidity (Current Ratio: 1.96)
Key Risks
Missing Altman Z-Score prevents full assessment of bankruptcy risk; potential red flag
Premium valuation: P/E of 30.28 exceeds forward P/E of 20.63 and may not fully reflect slowing growth
Bearish technical trend (0/100) and negative 1Y price return (-10.7%) suggest weak market sentiment
Insider selling activity: $3.34M in sales over last 6 months with no buys, including CEO transactions
Limited dividend appeal: low yield of 0.74% and weak Dividend Strength score of 25/100
AI Fair Value Estimate
Based on comprehensive analysis
$131.57
-2.6% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
71
Strong
60
82
88
85
40
AI Verdict
Moderately positive with caution due to valuation and insider activity
Key drivers: High Piotroski F-Score, Strong earnings growth and consistency, Premium valuation, Bearish technicals, Insider selling
Confidence
80%
Value
60/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 20.63 is reasonable for growth profile
- Intrinsic Value estimate of $131.57 close to current price
Watchpoints
- Current P/E of 30.28 is high relative to near-term growth
- Price/Sales and Price/Book ratios elevated at 5.51 and 5.67 respectively
Future
82/100
Ref Growth rates
Positives
- Revenue growth of 9.4% and earnings growth of 24.5% YoY
- Q/Q earnings growth remains strong at 23.6%
- Analyst target implies 25% upside
Watchpoints
No urgent risks highlighted.
Past
88/100
Ref Historical trends
Positives
- 24 out of 25 quarters beat EPS estimates
- Long history of positive earnings surprises averaging over 4% in recent years
- Stable and improving earnings trajectory since 2020
Watchpoints
No urgent risks highlighted.
Health
85/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 8/9 indicates excellent financial health
- Debt/Equity ratio of 0.53 shows conservative leverage
- Current and Quick Ratios above 1.4 indicate strong short-term liquidity
Watchpoints
- Altman Z-Score not available, limiting full solvency assessment
Dividend
40/100
Ref Yield, Payout
Positives
- Payout ratio of 21.71% is sustainable
Watchpoints
- Dividend yield of 0.74% is below market average
- Dividend Strength score very low at 25/100
- No data on dividend growth history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$135.05
Analyst Target
$169.67
Upside/Downside
+25.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for A and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
A
Agilent Technologies, Inc.
Primary
|
+11.4% | -11.3% | -10.7% | +12.8% | -2.2% | -3.3% |
|
MDLN
Medline Inc.
Peer
|
+15.2% | +15.2% | +15.2% | +15.2% | +13.9% | +7.6% |
|
ALC
Alcon Inc.
Peer
|
+8.8% | +9.9% | -9.6% | -12.6% | +0.1% | +1.6% |
|
ONC
BeOne Medicines AG
Peer
|
+4.7% | +20.8% | +34.0% | +1.2% | +10.5% | +2.5% |
|
ALNY
Alnylam Pharmaceuticals, Inc.
Peer
|
+114.5% | +67.5% | +29.6% | -32.7% | -2.8% | -2.3% |
A
Agilent Technologies, Inc.
Primary
5Y
+11.4%
3Y
-11.3%
1Y
-10.7%
6M
+12.8%
1M
-2.2%
1W
-3.3%
MDL
Medline Inc.
Peer
5Y
+15.2%
3Y
+15.2%
1Y
+15.2%
6M
+15.2%
1M
+13.9%
1W
+7.6%
ALC
Alcon Inc.
Peer
5Y
+8.8%
3Y
+9.9%
1Y
-9.6%
6M
-12.6%
1M
+0.1%
1W
+1.6%
ONC
BeOne Medicines AG
Peer
5Y
+4.7%
3Y
+20.8%
1Y
+34.0%
6M
+1.2%
1M
+10.5%
1W
+2.5%
ALN
Alnylam Pharmaceuticals, Inc.
Peer
5Y
+114.5%
3Y
+67.5%
1Y
+29.6%
6M
-32.7%
1M
-2.8%
1W
-2.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
30.28
Forward P/E
20.63
PEG Ratio
N/A
P/B Ratio
5.67
P/S Ratio
5.51
EV/Revenue
5.76
EV/EBITDA
20.47
Market Cap
$38.29B
Profitability
Profit margins and return metrics
Profit Margin
18.75%
Operating Margin
26.38%
Gross Margin
52.43%
ROE
20.62%
ROA
8.48%
Growth
Revenue and earnings growth rates
Revenue Growth
+9.4%
Earnings Growth
+24.5%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+23.6%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.53
Moderate
Current Ratio
1.96
Good
Quick Ratio
1.44
Good
Cash/Share
$6.31
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-25
$N/A
2025-11-24
$1.59
+0.4% surprise
2025-08-27
$1.37
+0.2% surprise
2025-05-28
$1.31
+3.6% surprise
Healthcare Sector Comparison
Comparing A against 373 companies in the Healthcare sector
(20 bullish, 125 neutral, 228 bearish)
P/E Ratio
30.28
This Stock
vs
90.37
Sector Avg
-66.5%
(Discount)
Return on Equity (ROE)
20.62%
This Stock
vs
-82.41%
Sector Avg
-125.0%
(Below Avg)
Profit Margin
18.75%
This Stock
vs
-14.05%
Sector Avg
-233.5%
(Weaker)
Debt to Equity
0.53
This Stock
vs
3.1
Sector Avg
-83.0%
(Less Debt)
Revenue Growth
9.4%
This Stock
vs
126.25%
Sector Avg
-92.6%
(Slower)
Current Ratio
1.96
This Stock
vs
4.61
Sector Avg
-57.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
A
Agilent Technologies, Inc.
|
NEUTRAL | $38.29B | 30.28 | 20.6% | 18.8% | $135.05 | |
|
MDLN
Medline Inc.
|
NEUTRAL | $38.33B | 33.02 | 6.5% | 4.1% | $47.22 | Compare |
|
ALC
Alcon Inc.
|
NEUTRAL | $39.59B | 38.6 | 4.8% | 10.3% | $80.29 | Compare |
|
ONC
BeOne Medicines AG
|
NEUTRAL | $36.75B | 124.98 | 7.5% | 5.4% | $319.94 | Compare |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
BEARISH | $41.57B | 135.09 | 73.3% | 8.4% | $313.41 | Compare |
A
Agilent...
NEUTRAL
Mkt Cap
$38.3B
P/E
30.3
ROE
20.6%
Price
$135.05
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-01 | DOLSTEN MIKAEL G | Director | Sale | 2,600 | $389,511 |
| 2025-11-26 | GONSALVES RODNEY | Officer | Sale | 3,000 | $464,956 |
| 2025-11-26 | GONSALVES RODNEY | Officer | Gift | 400 | $61,748 |
| 2025-11-18 | MCDONNELL PADRAIG | Chief Executive Officer | Sale | 911 | $130,492 |
| 2025-11-18 | MCDONNELL PADRAIG | Chief Executive Officer | Stock Award | 40,444 | - |
| 2025-11-18 | HENSON MEGHAN | Officer | Stock Award | 5,368 | - |
| 2025-11-18 | MAY SIMON | Officer | Stock Award | 6,781 | - |
| 2025-11-18 | RIEMANN ANGELICA | Officer | Stock Award | 8,274 | - |
| 2025-11-18 | KIRKWOOD JONAH PREVOST | Officer | Stock Award | 7,513 | - |
| 2025-11-18 | ZHANG JIANMIAO MIKE | Officer | Stock Award | 6,648 | - |
| 2025-11-18 | ELINOFF ADAM STEWART | Chief Financial Officer | Stock Award | 11,726 | - |
| 2025-11-18 | GONSALVES RODNEY | Officer | Stock Award | 4,942 | - |
| 2025-11-18 | DIMARCO BRET M | Officer | Stock Award | 6,922 | - |
| 2025-11-12 | MCDONNELL PADRAIG | Chief Executive Officer | Sale | 12,490 | $1,873,500 |
| 2025-11-12 | MCDONNELL PADRAIG | Chief Executive Officer | Option Exercise | 12,490 | $1,372,151 |
DOLSTEN MIKAEL G
Director
2025-12-01
2,600 shares
·
$389,511
GONSALVES RODNEY
Officer
2025-11-26
3,000 shares
·
$464,956
GONSALVES RODNEY
Officer
2025-11-26
400 shares
·
$61,748
MCDONNELL PADRAIG
Chief Executive Officer
2025-11-18
911 shares
·
$130,492
MCDONNELL PADRAIG
Chief Executive Officer
2025-11-18
40,444 shares
HENSON MEGHAN
Officer
2025-11-18
5,368 shares
MAY SIMON
Officer
2025-11-18
6,781 shares
RIEMANN ANGELICA
Officer
2025-11-18
8,274 shares
KIRKWOOD JONAH PREVOST
Officer
2025-11-18
7,513 shares
ZHANG JIANMIAO MIKE
Officer
2025-11-18
6,648 shares
ELINOFF ADAM STEWART
Chief Financial Officer
2025-11-18
11,726 shares
GONSALVES RODNEY
Officer
2025-11-18
4,942 shares
DIMARCO BRET M
Officer
2025-11-18
6,922 shares
MCDONNELL PADRAIG
Chief Executive Officer
2025-11-12
12,490 shares
·
$1,873,500
MCDONNELL PADRAIG
Chief Executive Officer
2025-11-12
12,490 shares
·
$1,372,151
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
18 analysts
HSBC
2026-01-20
Buy
Evercore ISI Group
2026-01-05
In-Line
Outperform
Barclays
2025-12-15
Equal-Weight
Overweight
Goldman Sachs
2025-12-09
Buy
Morgan Stanley
2025-12-02
Overweight
Citigroup
2025-11-25
Buy
Buy
UBS
2025-11-25
Buy
Buy
Wells Fargo
2025-11-25
Overweight
Overweight
JP Morgan
2025-11-25
Overweight
Overweight
Barclays
2025-11-25
Equal-Weight
Equal-Weight
Past News Coverage
Recent headlines mentioning A from our newsroom.
Newest → oldest
No matching news yet.